Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.02 EPS

Altimmune (NASDAQ:ALT) released its earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%.

Here are the key takeaways from Altimmune’s conference call:

• PERFORMA Phase III in MASH has begun enrolling across approximately 300 global sites, with management targeting the faster end of an 18–24-month enrollment window. The company expects the 52-week data readout in 2029.
• Pemvidutide produced statistically significant and clinically meaningful results in the RECLAIM Phase II alcohol use disorder trial, reducing heavy drinking days and improving key FDA-recognized measures including WHO risk-level reductions and zero heavy drinking days.
• Altimmune plans to seek an FDA end-of-Phase II meeting for AUD and believes a single global Phase III trial could satisfy U.S. and European requirements. Management is also evaluating inclusion of patients with BMI below 25, lower-dose options, and AUD patients with overlapping alcohol-related liver disease.
• Enrollment is complete in the approximately 120-patient RESTORE trial for alcohol-related liver disease, with top-line results expected in the second half of 2027. The amended analysis will assess liver stiffness at both 48 and 24 weeks to better characterize pemvidutide’s potential liver benefit.
• Altimmune ended June with approximately $519 million in cash, providing a runway through the MASH Phase III 52-week readout, but the balance does not fund a potential AUD Phase III program. The company expects to pursue non-dilutive financing such as partnerships, debt, or royalties rather than relying primarily on additional equity.

Altimmune Price Performance

ALT traded up $0.17 on Wednesday, hitting $3.17. 3,178,712 shares of the company were exchanged, compared to its average volume of 4,343,375. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56. The firm has a market capitalization of $616.48 million, a P/E ratio of -3.41 and a beta of 0.27. The business’s fifty day moving average is $2.90 and its 200 day moving average is $3.44.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Leerink Partners initiated coverage on shares of Altimmune in a research report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price objective on the stock. Citizens Jmp reduced their target price on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Wall Street Zen upgraded shares of Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Altimmune currently has an average rating of “Moderate Buy” and an average price target of $15.71.

Institutional Investors Weigh In On Altimmune

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after buying an additional 2,748 shares during the last quarter. Deutsche Bank AG boosted its stake in Altimmune by 4.0% in the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after buying an additional 3,047 shares during the last quarter. Arax Advisory Partners grew its holdings in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after buying an additional 5,253 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.